Centre Hospitalier Universitaire De La Reunion
- Address
- lock Available on a paid plan
Centre Hospitalier Universitaire De La Reunion - Comprehensive Cancer and Specialty Care Research Center
The Centre Hospitalier Universitaire De La Reunion is a distinguished academic medical center engaged in extensive clinical research across multiple therapeutic domains. The center demonstrates particular strength in oncology research, with active participation in international trials spanning solid tumors, hematological malignancies, and pediatric cancers. Their research portfolio reflects a commitment to advancing precision medicine approaches and evaluating novel therapeutic combinations across diverse patient populations.
- Oncology research including lung cancer, cervical cancer, lymphomas, and advanced solid tumors with focus on immunotherapy combinations
- Pediatric oncology and rare tumor research encompassing neuroblastoma, retinoblastoma, sarcomas, and brain tumors
- Hematological malignancies including multiple myeloma, acute leukemias, and myeloproliferative neoplasms
- Infectious disease studies, cardiovascular trials, and specialized pediatric conditions
The center's research expertise extends beyond oncology to include critical care interventions, emergency medicine protocols, and rare disease investigations. Notable involvement in collaborative international networks demonstrates their capacity for conducting complex multi-arm adaptive trials and precision medicine studies utilizing advanced biomarker stratification. The institution also contributes to infectious disease research particularly relevant to their geographic location, including chikungunya vaccine effectiveness studies in vulnerable populations, alongside trials in dermatology, nephrology, and autoimmune conditions such as systemic lupus erythematosus.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 133 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 126 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Institut Gustave Roussy4active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Institut Gustave Roussy5trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De La Reunion
lock Showing 1 of 61 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Non-Inferiority Trial of Doxycycline Monohydrate Versus Benzathine Benzylpenicillin for the Treatment of Early Syphilis | Assistance Publique Hopitaux De Paris | Phase III | Not Recruiting | Dec 2021 | Jul 2025 |
IMP list
lock Showing 1 of 133 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vincristine Sulfate | 11 | Unknown | 2010-03-18 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.